drugset / Trial / NCT00027664

Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer

NCT00027664

Phase 2 Unknown 90 enrolled Cancer Research UK
RandomizedTreatment

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if interferon alfa is more effective with or without thalidomide in treating metastatic kidney cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of interferon alfa with or without thalidomide in treating patients who have metastatic kidney cancer.

Timeline

Start
2001-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified Oral
Subject interferon alfa-2b Protein / enzyme biologic Subcutaneous

Indications